Seminars in Nuclear Medicine
Volume 31, Issue 4 , Pages 260-277 , October 2001

Evolution of Tc-99m in diagnostic radiopharmaceuticals

References 

  1. Perrier C, Segré E. Radioactive isotopes of element 43. Nature. 1937;140:193–194
  2. Perrier C, Segré E. Some chemical properties of element 43. J Chem Phys. 1937;4:712–716
  3. Segré E, Wu CS. Some fission products of uranium. Phys Rev. 1940;57:552
  4. Paneth FA. The making of missing chemical elements. Nature. 1947;159:8–10
  5. Seaborg GT, Segré E. Nuclear isomerism of element 43. Phys Rev. 1939;55:808
  6. Molinski VJ. A review of 99mTc generator technology. Int J Appl Radiat Isot. 1982;33:811–819
  7. Richards P, Tucker WD, Srivastava SC. Introduction: Technetium-99m: An historical perspective. Int J Appl Radiat Isot. 1982;33:793–799
  8. Boyd RE. Technetium-99m Generators: The available options. Int J Appl Radiat Isot. 1982;33:801–809
  9. Richards P. A survey of the production at Brookhaven National Lab of the isotopes for medical research. In: Trans 5th Nuclear Congress, 7th Int. Electronic and Nuclear Symp. Rome. June 1960;p. 225
  10. Harper PV, Beck R, Charleston D, et al. Optimization of scanning method using Tc-99m. Nucleonics. 1964;22:50
  11. Richards P. In: Proc. Symp. Radioactive Pharmaceuticals. ORNL 1965. 1965;p. 323–334
  12. Smith EM. Properties, uses, radiochemical purity and calibration of Tc-99m. J Nucl Med. 1964;5:871–882
  13. Srivastava SC, Richards P. Technetium-99m labeled compounds. In: Rayudu GVS editors. Radiotracers for Medical Applications. Boca Raton, FL: CRC Press Inc; 1983;p. 107–185
  14. Harper PV, Andros G, Lathrop KA. Semi annual report to the Atomic Energy Commission, September 1962. ACRH-18. 1962;76–87
  15. Schwochau K. Technetium radiopharmaceuticals-Fundamentals, synthesis, structure, and development. Angew Chem Int Ed Engl. 1994;33:2258–2267
  16. Britton KE. The development of new radiopharmaceuticals. Eur J Nucl Med. 1990;16:373–385
  17. Deutsch EA, Libson K, Jurisson S. Technetium chemistry and technetium radiopharmaceuticals. In: Lippard SJ editors. Progress in Inorganic Chemistry. New York: John Wiley & Sons, Inc; 1983;p. 75–139
  18. Nowotnik DP. Physicochemical concepts in the preparation of technetium radiopharmaceuticals. In: Sampson CB editors. Textbook of Radiopharmacy Theory and Practice. ed 2. Amsterdam: Gordon and Breach Science Publisher; 1994;p. 29–49
  19. Loberg MD, Cooper M, Harvey E. Development of new radiopharmaceuticals based on N-substitution of iminodiacetic acid. J Nucl Med. 1976;17:633–638
  20. Nunn AD, Loberg MD, Conley RA. A structure-distribution relationship approach leading to the development of 99mTc-mebrofenin. An improved chole-scintigraphic agent. J Nucl Med. 1983;24:423–430
  21. In: Nunn AD editors. Radiopharmaceuticals Chemistry and Pharmacology. Vol 55:New York: Marcel Dekker, Inc; 1992;
  22. Nicolini M, Bandoli G, Mazzi U. In: Technetium and Rhenium in Chemistry and Nuclear Medicine. New York: Verona and Raven Press; 1990;
  23. Subramanian G, McAfee JG. A new complex of Tc-99m for imaging. Radiology. 1971;99:192–196
  24. Subramanian G, McAfee JG. New developments in radiopharmaceuticals for imaging. A review. In: Medical Radionuclide Imaging. Vol I:IAEA; 1980;p. 429–452
  25. Subramanian G, McAfee JG, Blair RJ, et al. 99mTc-EHDP: A potential radiopharmaceutical for skeletal imaging. J Nucl Med. 1972;13:947–950
  26. Subramanian G, McAfee JG, Blair RJ, et al. Technetium-99m methylene diphosphonate-A superior agent for skeletal imaging: Comparison with other technetium complexes. J Nucl Med. 1975;16:744–755
  27. (communications to the editor) Libson K, Deutsch E, Barnett BL. Structural characterization of a 99Tc-diphosphonate complex. Implications for the chemistry of 99mTc-skeletal imaging agents. J Am Chem Soc. 1980;102:2476–2478
  28. Swanson DP, Chilton HM, Thrall JH. In: Pharmaceuticals in Medical Imaging. New York: McMillan Publishing Co; 1990;
  29. Orlandi C, Crane PD, Edwards DS, et al. Early scintigraphic detection of experimental myocardial infarction in dogs with technetium-99m-glucaric acid. J Nucl Med. 1991;32:263–268
  30. Bandoli G, Mazzi U, Roncari E, et al. Crystal structures of coordination compounds. Coord Chem Rev. 1982;44:191–227
  31. Melnik M, Lier J Van. Analysis of structural data of technetium compounds. Coord Chem Rev. 1987;77:275–324
  32. Clarke MJ, Podbielsky L. Medical diagnostic imaging with complexes of 99mTc. Coord Chem Rev. 1987;78:253–331
  33. Steigman J, Eckelman WC. In: The Chemistry of Technetium in Medicine. Washington DC: National Academy Press; 1992;
  34. Tisato F, Refosco F, Bandoli G. Structural survey of technetium complexes. Coord Chem Rev. 1994;135/136:325–397
  35. Fritzberg AR, Lewis D. HPLC analysis of Tc-99m iminodiacetate hepatobiliary agents and a question of multiple peaks: Concise communications. J Nucl Med. 1980;21:1180–1184
  36. Astheimer L, Linse KH, Ramamoorthy N, et al. Synthesis, characterization and evaluation of 99mTc/99Tc-DIARS and DMPE complexes containing pentadecanoic acid. Nucl Med Biol. 1987;14:545–553
  37. Ramamoorthy N, Pillai MRA, Troutner DE. Studies on some aspects of the instability of Tc-hexamethyl propylene amine-oxime (Tc-HMPAO). Nucl Med Biol. 1993;20:307–310
  38. Troutner DE, Volkert WA, Holmes RA. Labeling of amine ligands with 99mTc in aqueous solutions by ligand exchange. Int J Appl Radiat Isot. 1982;33:891–896
  39. Pillai MRA, Kothari K. Ligand exchange labeling of amine-phenols with 99mTc. Appl Radiat Isot. 1993;44:911–915
  40. Pandey PM, Sachdev SS, Ramamoorthy N, et al. Formulation and evaluation of a two-component lyophilized kit for Tc-Sestamibi: Transchelation preparation of 99mTc-Sestamibi. Nucl Med Biol. 1997;24:697–700
  41. Vanaja R, Solav SV, Joshi SH, et al. Preparation of 99mTc-ethylene dicysteine by transchelation using 99mTc-GHA and its evaluation for renal function studies. Nucl Med Commun. 2000;21:977–982
  42. (Letter to the editor) Oldendorf WH. Need for new radiopharmaceuticals. J Nucl Med. 1978;19:1182
  43. Verbruggen AM. Radiopharmaceuticals: State of the art. Eur J Nucl Med. 1990;17:346–364
  44. Volkert WA, Hoffman TJ, Seger TM, et al. 99mTc-propyleneamine oxime (Tc-99m-PnAO): A potential brain radiopharmaceutical. Eur J Nucl Med. 1984;11:511–516
  45. Nowotnik DP, Canning LR, Cumming SA, et al. Development of a Tc-99m-labelled radiopharmaceutical for cerebral blood flow imaging. Nucl Med Commun. 1985;6:499–506
  46. Neirinckx RD, Canning LR, Piper IM, et al. Technetium-99m d,l-HM-PAO: A new radiopharmaceutical for SPECT imaging of regional cerebral blood perfusion. J Nucl Med. 1987;28:191–202
  47. Hoffman TJ, Corlija M, Reitz R, et al. Biological evaluation of the Tc-99m complexes of the d and 1 isomer of HMPAO. J Nucl Med. 1992;33:1032
  48. Kung HF. Brain radiopharmaceuticals. In: Fritzberg AR editors. Radiopharmaceuticals: Progress and Clinical Perspectives. Vol I:Boca Raton: CRC Press; 1986;p. 21–39
  49. Hung JC, Volkert WA, Holmes RA. Stabilization of technetium-99m, D,L-hexamethylpropyleneamine oxime (99mTc-D,L-HM-PAO) using gentisic acid. Nucl Med Biol. 1989;16:675–680
  50. Tubergen K, Corlija M, Volkert WA, et al. Sensitivity of technetium-99m-d,l-HMPAO to radiolysis in aqueous solutions. J Nucl Med. 1991;32:111–115
  51. (abstr) Wang SJ, Kao CH, Wey SP. Trial of labeling leucocytes with stabilized 99mTc-D,L-HM-PAO by methylene blue. Eur J Nucl Med. 1997;24:1040
  52. (abstr) Walovitch RC, Makuch J, Knapik G, et al. Brain retention of Tc-99m-ECD is related to in vivo metabolism. J Nucl Med. 1988;29:747
  53. Pillai MRA, John CS, Lo JM. Radiochemical studies of tetradentate amine-phenols. Appl Radiat Isot. 1990;41:557–561
  54. Pillai MRA, Kothari K, Schlemper EO, et al. Technetium complexes of tetradentate chiral amine-phenol ligands. Appl Radiat Isot. 1993;44:1113–1118
  55. Pillai MRA, Corlija M, Volkert WA. Technetium-99m complexes of tetradentate amine-phenol ligands: Minor differences in the ligand structure give Tc complexes with significantly different biolocalization. Ind J Nucl Med. 1997;12:204–210
  56. Pillai MRA, Kothari K, Jurisson S. Pentadentate chiral aminephenol ligands. Appl Radiat Isot. 1995;46:923–927
  57. Pillai MRA, John CS, Lo JM. Technetium complexes of pentadentate amine-phenol ligands. Nucl Med Biol. 1993;20:211–216
  58. Troutner DE, Pillai MRA, Lo JM, et al. Pentadentate amine phenol complexes of 99mTc. In: Nicolini M, Bandoli G, Mazzi U editor. Technetium and Rhenium in Chemistry and Nuclear Medicine. Vol 3:Verona, Italy: Cortina International; 1990;p. 585–593
  59. Baidoo KE, Lever SZ. Evaluation of diamine dithiol-based bifunctional chelate for labeling small molecule with 99mTc. In: Nicolini M, Bandoli G, Mazzi U editor. Technetium and Rhenium in Chemistry and Nuclear Medicine. Vol 3:Verona, Italy: Cortina International; 1990;p. 369–374
  60. Scheffel U, Goldfarb HW, Lever SZ, et al. Comparison of Tc-99m aminoalkyl diaminodithiol (DADT) analogs as potential brain blood flow imaging agents. J Nucl Med. 1988;29:73–82
  61. Chiotellis E, Varvarigou AD, Maina TH, et al. Comparative evaluation of Tc-99m labeled aminothiols as possible brain perfusion imaging agents. Nucl Med Biol. 1988;15:215–223
  62. Kung HF, Molnar M, Billings J, et al. Synthesis and biodistribution of neutral lipid soluble Tc-99m complexes which cross the blood-brain barrier. J Nucl Med. 1984;25:543–549
  63. Mahmood A, Baidoo KE, Lever SZ. Stereoisomers of neutral oxotechnetium (V) and oxorhenium (V) complexes. In: Nicolini M, Bandoli G, Mazzi U editor. Technetium and Rhenium in Chemistry and Nuclear Medicine. Vol 3:Verona, Italy: Cortina International; 1990;p. 119–124
  64. (abstr) Goldfarb HW, Scheffel U, Lever SZ, et al. Comparison of Tc-99m aminoethyl diamidodithiol analogues for brain, blood-flow imaging. J Nucl Med. 1986;27:1050
  65. (abstr) Baidoo KE, Epps LA, Scheffel U, et al. Pulmonary accumulation of Tc-99m diaminodithiol (DADT) complexes. J Nucl Med. 1987;28:729
  66. Morgan GF, Deblaton M, Clemens P, et al. 99mTc-MRP20. A potential brain perfusion agent: In vivo distribution and SPECT studies in non primate animals. J Nucl Med. 1991;32:500–505
  67. Nunn AD, Feld T, Narra RK. Quantitative structure distribution relationships (QSDRs) of BATOs. In: Nicolini M, Bandoli G, Mazzi U editor. Technetium and Rhenium in Chemistry and Nuclear Medicine. Vol 3:Verona, Italy: Cortina International; 1990;p. 399–404
  68. Nowotnik DP, Nunn AD. Technetium compounds for imaging myocardial and cerebral perfusion. Drug News Perspec. 1992;5:174–183
  69. Narra RK, Nunn AD, Kuczynski BL. A neutral lipophilic technetium-99m complex for regional cerebral blood flow imaging. J Nucl Med. 1990;31:1370–1377
  70. Johannsen B, Spies H. Progress and problems in the chemistry of Technetium-99m tracers. Isotopenpraxis. 1988;24:449–454
  71. Singh PR, Corlija M, Troutner DE, et al. Synthesis, characterization and biodistribution studies of a neutral-lipophilic Tc-99m N3S2 chelate. Nucl Med Biol. 1992;19:791–795
  72. Deutsch E, Bushong KA, Glavan RC, et al. Heart imaging with cationic complexes of technetium. Science. 1981;214:85–86
  73. Dean RT, Wester DW, Nosco DL, et al. Progress in the evaluation and development of Tc-99m radiopharmaceuticals. In: Nicolini M, Bandoli G, Mazzi U editor. Technetium in Chemistry and Nuclear Medicine. Vol 2:New York: Verona and Raven Press; 1986;
  74. Deutsch E, Glavan KA, Sodd VJ. Cationic Tc-99m complexes as potential myocardial imaging agents. J Nucl Med. 1981;22:897–907
  75. Gerson MC, Deutsch EA, Nishiyama H, et al. Myocardial perfusion imaging with 99mTc-DMPE in man. Eur J Nucl Med. 1983;8:371–374
  76. Jones AG, Abrams MJ, Davison A, et al. Biological studies of a new class of technetium complexes: The hexakis(alkylisonitrile)-technetium (I) cations. Nucl Med Biol. 1984;11:225–234
  77. (abstr) Mousa SA, Williams SJ. Myocardial uptake and retention of Tc-99m-hexakis-aliphatic isotnitriles: Evidence for specificity. J Nucl Med. 1986;27:995
  78. Wieland DM, Deutsch EA. Cationic radiotracers as myocardial radiopharmaceuticals: Progress and clinical perspectives. In: Fritzberg AR editors. Radiopharmaceuticals: Progress and Clinical Perspectives. Vol I:Boca Raton: CRC; 1986;p. 1–20
  79. Ramamoorthy N. Studies on the preparation and evaluation of a few technetium radiopharmaceuticals. In: PhD Thesis. Bombay, India: University of Bombay; 1987;
  80. Nunn AD. Single photon radiopharmaceuticals for imaging myocardial perfusion. In: Nunn AD editors. Radiopharmaceuticals: Chemistry and Pharmacology. New York: Marcell Dekker Inc; 1992;p. 97–139
  81. Jurisson S, Berning D, Jia W, et al. Coordination compounds in nuclear medicine. Chem Rev. 1993;93:1137–1156
  82. Baldas J, Bonnyman J. Substitution reactions of 99mTcNCl4: A route to a new class of 99mTc-radiopharmaceuticals. Int J Appl Radiat Isot. 1985;36:133–139
  83. Baldas J, Bonnyman J. Effect of 99mTc-nitrido group on the behaviour of 99mTc radiopharmaceuticals. Int J Appl Radiat Isot. 1985;36:919–923
  84. Pasqualini R, Duatti A, Bellande E, et al. Bis(dithiocarbamato)nitrido technetium-99m radiopharmaceuticals: A class of neutral myocardial imaging agents. J Nucl Med. 1994;35:11–12
  85. Kelly JD, Higly B, Archer CM, et al. Technetium-99m complexes of functionalised diphosphines for myocardial imaging. In: Nicolini M, Bandoli G, Mazzi U editor. Technetium and Rhenium in Chemistry and Nuclear Medicine. Vol 3:Verona Italy: Cortina International; 1990;p. 405–412
  86. Libson K, Messa C, Kwiatkowski M, et al. Development of new 99mTc myocardial perfusion imaging agents. In: Nicolini M, Bandoli G, Mazzi U editor. Technetium and Rhenium in Chemistry and Nuclear Medicine. Vol 3:Verona Italy: Cortina International; 1990;p. 365–368
  87. (abstr) Lahiri A, Highley B, Crawley JCW, et al. Novel functionalised diphosphine complexes of Tc-99m for myocardial imaging in man. J Nucl Med. 1989;30:818
  88. Higley B, Smith FW, Smith T, et al. Technetium-99m-1,2-bis-(bis[2-ethoxyethyl]phosphino)ethane: Human biodistribution, dosimetry and safety of a new myocardial perfusion imaging agent. J Nucl Med. 1993;34:30–38
  89. (abstr) Smith FW, Smith T, Gemmell H, et al. Phase I study of Tc-99m diphosphine (P53) for myocardial imaging. J Nucl Med. 1991;32:967
  90. Deutsch E, Ketring AR, Libson K, et al. The Noah's ark experiment: Species dependent biodistributions of cationic 99mTc complexes. Nucl Med Biol. 1989;16:191–232
  91. Jurisson S, Lindoy LF, Dancey KP, et al. New oxotechnetium (V) complexes of N,N′-ethylene bis(acetylacetone imine), N,N′-ethylene(salicylideneamine), and O'phenylenebis(salicylidene amine). X-ray structures of the complexes of N, N′-ethylene bis(acetylacetone imine) and N,N′-ethylene(salicylideneamine). Inorg Chem. 1984;23:227–231
  92. Rossetti C, Vanoli G, Paganelli G, et al. Human biodistribution, dosimetry and clinical use of technetium (III)-99m-Q12. J Nucl Med. 1994;35:1571–1580
  93. Despopoulos AJ. A definition of substrate specificity in renal transport of organic anions. J Theor Biol. 1965;8:163–192
  94. Fritzberg AR, Kuni CC, et al. Synthesis and biological evaluation of Technetium-99m N,N′-bis(mercaptoacetyl)-2,3-diaminopropionate: A potential replacement for I-131-o-iodohippurate. J Nucl Med. 1982;23:223–229
  95. Fritzberg AR, Nunn AD. Radio-HPLC: Application to organic and metal chelate chemistry in analytical and chromatographic techniques. In: Wieland DM, Tobes MC, Mangner TJ editor. Analytical and Chromatographic Techniques in Radiopharmaceutical Chemistry. New York: Springer Verlag; 1986;p. 183–212
  96. Fritzberg AR, Kasina S, Eshima D, et al. Synthesis and biological evaluation of Technetium-99m-MAG3 as a hippuran-replacement. J Nucl Med. 1986;27:111–116
  97. Noll B, Johannsen B, Muenze R, et al. Two-component kit with nonradioactive precursor for the preparation of an enantiomeric form of the kidney function diagnostic agent, Technetium-99m-labeled mercaptoacetyltriglycine. Eur Pat Appl EP. 1991;427:360
  98. Brandau W, Bubek B, Eisenhut M. Technetium-99m-labeled renal function and imaging agent: Synthesis of 99mTc-MAG3 and biodistribution of by-products. Appl Radiat Isot. 1988;39:121–129
  99. Nosco DL, Tofe AJ, Dunn TJ, et al. New developments in radiopharmaceuticals in Mallinckrodt. In: Nicolini M, Bandoli G, Mazzi U editor. Technetium and Rhenium in Chemistry and Nuclear Medicine. Vol 3:Verona Italy: Cortina International; 1990;p. 405–412
  100. Bormans G, Cleynhens B, Hoogmartens M, et al. Evaluation of 99mTc mercaptoacetyltripeptides in mice and a baboon. Nucl Med Biol. 1992;19:375–388
  101. Verbruggen AM, Nosco DL. Tc-99m-L,L-ethylene dicysteine as a renal imaging agent. I. Labeling and evaluation in animals. J Nucl Med. 1982;33:551–557
  102. Verbruggen AM, Bormans G, et al. Isolation of the monoester, monoacid derivatives of 99mTc-ECD and their biodistribution in mice. In: Nicolini M, Bandoli G, Mazzi U editor. Technetium and Rhenium in Chemistry and Nuclear Medicine. Vol 3:Verona, Italy and Raven Press, New York: Cortina International; 1990;p. 445–452
  103. Sen K, Chatterjee M, Banerjee S, et al. Development of a new renal tubular agent, 99mTc-dimethylester of DTPA (DMDTPA): Preparation and evaluation of a lyophilized kit for 99mTc-DMDTPA. Ind J Nucl Med. 1996;11:227
  104. (abstr) Padhy AK, Solanki K, Britton KE, et al. A potential new cationic renal tubular agent: Evaluation in normal human volunteers of Tc-99m-diaminocyclohexane (DACH). J Nucl Med. 1992;33:923
  105. Oyen WJG, Boerman OC, van der Laken CJ, et al. The uptake mechanisms of inflammation- and infection-localizing agents. Eur J Nucl Med. 1996;23:459–465
  106. Chianelli M, Mather SJ, Martin-Comin J, et al. Radiopharmaceuticals for the study of inflammatory processes: A review. Nucl Med Commun. 1997;18:437–455
  107. McAfee JG, Thakur ML. Survey of radioactive agents for in-vitro labeling of phagocytic leukocytes. I. Soluble agents. J Nucl Med. 1976;17:480–487
  108. McAfee JG. Editorial: What is the best method for imaging focal infections?. J Nucl Med. 1990;31:413–416
  109. Danpure HJ, Osman S. Radiolabeling of blood cells: Methodology. In: Sampson CB editors. Textbook of Radiopharmacy: Theory and Practice. 2nd ed. Amsterdam: Gordon and Breach Science Pub; 1994;p. 75–86
  110. Weisner PS, Bower GR, Dollimore LA, et al. A method for stabilizing technetium-99m exametazime prepared from a commercial kit. Eur J Nucl Med. 1993;20:661–666
  111. Ozker K, Collier BD, Krasnow AZ, et al. Evaluation of 99mTc-ECD as a white blood cell labeling agent. Nucl Med Commun. 1997;18:540–542
  112. Corlija M, Volkert WA, John CS, et al. Biolocalization and cell labeling properties of neutral-lipophilic 99mTc-amine phenol chelates. Nucl Med Biol. 1990;18:167–172
  113. Ramamoorthy N. 99mTc complexes for functional imaging: Genesis of development and recent trends. Ind J Nucl Med. 1998;13:79–94
  114. Claessens RAMJ, Koenders EB, Oyen WJG, et al. Retention of Technetium-99m in infectious foci in rats after release from Technetium-99m-labeled human non-specific polyclonal immunoglobulin G: A duallabel study with hydrazinonicotinamido and iminothiolano immunoglobulin. Eur J Nucl Med. 1996;23:1536–1539
  115. Abrams MJ, Juweid M, ten Kate CI, et al. Tc-99m-human polyclonal IgG radiolabelled via the hydrazino nicotinamide derivative for imaging focal sites of infection of rats. J Nucl Med. 1990;31:2022–2028
  116. Liu S, Edwards SD. 99mTc-labeled small peptides as diagnostic radiopharmaceuticals. Chem Rev. 1999;99:2235–2268
  117. Vinjamuri S, Hall AV, Solanki KK, et al. Comparison of 99mTc-infecton imaging with radiolabeled white cell imaging in the evaluation of bacterial infection. Lancet. 1996;347:233–235
  118. Gano L, Patricio L, Cantinho G, et al. Ciprofloxacin in imaging of infective versus sterile inflammation. Modern Trends in Radiopharmaceuticals for Diagnosis and Therapy. IAEA-TECDOC-1029, Vienna. 1998;213–220
  119. Welling MM, Paulusma-Annema A, Balter HS, et al. Technetium-99m-labelled antimicrobial peptides discriminate between bacterial infections and sterile inflammations. Eur J Nucl Med. 2000;27:292–301
  120. Nibbering PH, Welling MM, Van den Brock PJ, et al. Radiolabelled antimicrobial peptides for imaging of infection. Nucl Med Commun. 1998;19:1117–1121
  121. Hiemstra PS, Van den Barselaar MT, Roest M, et al. Ubiquicidin, a novel murine antimicrobial protein in the cytosolic fraction of activated macrophages. J Leucocyte Biol. 1999;66:423–428
  122. Rusckowski M, Qu T, Pullman J, et al. Inflammation and infection imaging with a 99mTc-neutrophil elastase inhibitor in monkeys. J Nucl Med. 2000;41:363–374
  123. Hnatowich DJ, Qu T, Chang F, et al. Labeling peptides with Tc-99m using a bifunctional chelator of a N-hydroxy succinimide ester of mercaptoacetyl triglycine. J Nucl Med. 1998;39:56–64
  124. Kipper SL, Rypins EB, Evans DG, et al. Neutrophil-specific 99mTc-labeled anti-CD15 monoclonal antibody imaging for diagnosis of equivocal appendicitis. J Nucl Med. 2000;412:449–455
  125. Thakur ML, Marcus CS, Henneman P, et al. Technetium-99m-labeled anti-SSEA-1 antibody for human neutrophils: In vivo evaluation and assessment as an agent for imaging infectious diseases. J Nucl Med. 1996;37:1789–1795
  126. Yokoyama A, Hata N, Horiuchi K, et al. The design of pentavalent 99mTc-dimercaptosuccinate complex as a tumour imaging agent. Int J Nucl Med Biol. 1985;12:273–279
  127. Ramamoorthy N, Shetye SV, Pandey PM, et al. Preparation and evaluation of 99mTc(V)-DMSA complex: Studies in medullary carcinoma of thyroid. Eur J Nucl Med. 1987;12:623–628
  128. Bhatnagar A, Sharma R, Mondal A, et al. Tumour imaging using Tc-99m-citrate. Ind J Nucl Med. 1997;12:77–83
  129. Blower PJ, Singh J, Clarke SEM. The chemical identity of pentavalent technetium-99m-dimercaptosuccinic acid. J Nucl Med. 1991;32:845–849
  130. Ramamoorthy N, Prabhakar G. Radiopharmaceuticals for oncology: Status and newer trends—An overview. Ind J Nucl Med. 1997;12:97–103
  131. Abdel Dayem HM, Scott AM, Macapinlac HA, et al. Role of 201TlCl and 99mTc-sestamibi in tumour imaging. In: Freeman LM editors. Nuclear Medicine Annual. New York Press; 1994;p. 181–234
  132. Rambaldi PF, Mansi L, Procaccini E, et al. Breast cancer detection with Tc-99m-Tetrofosmin. Clin Nucl Med. 1995;20:703–705
  133. Suess E, Malessa S, Ungersbock K, et al. Technetium-99m-d,l-hexamethylpropyleneamineoxime (HMPAO) uptake and glutathione content in brain tumors. J Nucl Med. 1991;32:1675–1681
  134. (abstr) Ravichandran R, Devaru S, Prakash R, et al. Kinetics of 99mTc-GHA in human cerebral gliomas. Ind J Nucl Med. 1990;5:36
  135. Hnatowich DJ, Winnard P, Virzi F, et al. Technetium-99m labeling of DNA oligonucleotides. J Nucl Med. 1995;36:2306–2314
  136. Martin GV, Caldwell JH, Graham MM, et al. Non-invasive detection of hypoxic myocardium using fluorine-18-fluoromisonidazole and positron emission tomography. J Nucl Med. 1992;33:2202–2208
  137. Linder KE, Chan YW, Cyr JE, et al. TcO (PnAO-1-2-nitroimidazole) [BMS181321], a new technetium-containing nitroimidazole complex for imaging hypoxia: Synthesis, characterization and xanthine oxidase-catalysed reduction. J Med Chem. 1994;37:9–17
  138. Di rocco RJ, Kuczynski BL, Pirro JP. Imaging ischemic tissue at risk of infarction during stroke. J Cereb Blood Flow Metab. 1993;13:755–762
  139. Ramalingam K, Raju N, Nanjappan P, et al. The synthesis and in vitro evaluation of a 99mTechnetium-nitroimidazole complex based on a bis(amine-phenol) ligand: Comparison to BMS-181321. J Med Chem. 1994;37:4155–4163
  140. Johnson G, Nguyen KN, Liu ZG, et al. Technetium-99m HL-91: A potential new marker of myocardial viability assessed by nuclear imaging early after reperfusion. J Nucl Cardiol. 1998;5:285–294
  141. Kneiss T, Spies H, Brandau W, et al. Nicotinamide-substituted complexes as redox markers. I. Synthesis and UV estimation of rhenium and technetium mixed-ligand systems. J Labelled Compd Radiopharm. 1998;41:605–614
  142. Production of 99mTc radiopharmaceuticals for brain, heart and kidney imaging. In: IAEA TECDOC-805. Vienna: International Atomic Energy Agency; 1995;
  143. Sundberg MW, Meares CF, Goodwin DA, et al. Chelating agents for the binding of metal ions to macromolecules. Nature. 1974;250:587–588
  144. Griffiths GL, Goldenberg DM, Jones AL, et al. Radiolabeling of monoclonal antibodies and fragments with technetium and rhenium. Bioconjugate Chem. 1992;3:91–99
  145. Mather SJ. In: Current Directions in Radiopharmaceutical Research and Development. London: Kluwer Academic Pub; 1996;
  146. Jurisson S, Schlemper EO, Troutner DE, et al. Synthesis, characterization and x-ray structural determination of Technetium-(V)-oxotetradentate amine-oxime complexes. Inorg Chem. 1986;25:543–549
  147. Davison A, Jones AG, Orvig C, et al. A new class of oxotechnetium(V) chelate complexes containing a TcON2S2 core. Inorg Chem. 1981;20:1629–1632
  148. Brenner D, Davison A, Lister-James J, et al. Synthesis and characterization of a series of isomeric oxotechnetium(V) diamidodithiolates. Inorg Chem. 1984;23:3793–3797
  149. Verona and Raven Press Edwards DS, Cheeseman EH, Watson MW, et al. Synthesis and characterization of technetium and rhenium complexes of N,N′-1,2-ethylenediylbis-L-cysteine. Neurolite and its metabolites. In: Nicolini M, Bandoli G, Mazzi U editor. Technetium and Rhenium in Chemistry and Nuclear Medicine. Vol 3:New York: Cortina International; 1990;p. 433–444
  150. Grummon G, Rajagopalan R, Palenik GJ, et al. Synthesis and characterization and crystal structures of technetium(V) oxo complexes useful in nuclear medicine. I. Complexes of Mercaptoacetyl glycylglycylglycine MAG3 and its methyl ester derivative (MAG3OMe). Inorg Chem. 1995;34:1764–1772
  151. Johannsen B, Noll B, Leibnitz P, et al. Technetium and rhenium complexes of mercapto-containing peptides. I. Tc(V) and Re(V) complexes with mercaptoacetyl diglycine (MAG2) and x-ray structure of AsPh4[TcO(MAG2)].C2H5OH. Inorg Chim Acta. 1993;210:209–214
  152. John CS, Francesconi LC, Kung HF, et al. Synthesis and characterization of neutral oxotechnetium (V) bis aminoethane thiol complexes: Potential brain imaging agents. Polyhedron. 1992;11:1145–1155
  153. Wong E, Fauconnier T, Bennett S, et al. Rhenium (V) and Technetium (V) oxo complexes of an N2N′S peptidic chelator: Evidence of interconversion between the syn and anti conformations. Inorg Chem. 1997;36:5799–5808
  154. Najafi A, Alauddin MM, Siegel ME, et al. Synthesis and preliminary evaluation of a new chelate N2S4 for use in labeling proteins with metallic radionuclides. Nucl Med Biol. 1991;18:179–185
  155. Zuckman SA, Freeman GM, Troutner DE, et al. Preparation and x-ray structure of trans-dioxo(1,4,8,11-tetraazacyclotetradecane) technetium(V) perchlorate hydrate. Inorg Chem. 1981;20:2386–2389
  156. Jurisson S, Aston K, Fair C, et al. Effect of ring size on properties of technetium amine complexes. X-ray structures of TcO2[Pent(AO)2] which contains an unusual eight-membered chelate ring and of TcOE-n(AO)2. Inorg Chem. 1987;26:3576–3582
  157. Franz J, Volkert WA, Barefield EK, et al. The production of 99mTc-labelled conjugated antibodies using a cyclam-based bifunctional chelating agent. Nucl Med Biol. 1987;14:569–577
  158. Thakur ML, Kolan H, Li J, et al. Radiolabelled somatostatin analogs in prostate cancer. Nucl Med Biol. 1997;24:105–113
  159. Pillai MRA, Lo JM, John CS, et al. μ-oxo-bis-oxo complexes of Tc(V) with amine phenol ligands: Synthesis, characterization and x-Ray crystal structures. Inorg Chem. 1990;29:1850–1856
  160. Bandoli G, Nicolini M, Mazzi U, et al. Synthesis and characterization of Technetium (V) Oxo-complexes with quadridentate Schiff-base ligands: X-ray structures of μ-oxo-bis-{oxo[N,N′-propane-1,3-diyl-bis(salicylideneiminato)] technetium(V)} and chloro-oxo[N,N′-propane-1,3-diylbis(salicylideneiminato)] technetium(V). J Chem Soc Dalton Trans. 1984;2505–2511
  161. Clarke MJ, Kastner ME, Podbielski LA, et al. Low-symmetry, mixed-valent, μ-Oxo technetium complexes with pyridine and halide ligands. J Am Chem Soc. 1988;110:1818–1827
  162. Pillai MRA, Barnes CL, Schlemper EO. Dinuclear complexes of Re(V) with amine-phenol ligands. Syntheses, characterization and x-ray crystal structures. Polyhedron. 1994;13:701–708
  163. Baldas J, Bonnyman J, Williams GA. Studies of Tc complexes 9. Use of tetrachloronitridotechnetate (VI) anion for the preparation of nitrido complexes of technetium. Crystal structure of bis(8-quinolinethiolato)nitridotechnetium(V). Inorg Chem. 1986;25:150–153
  164. Archer CM, Dilworth JR, Jobanputra P, et al. Development of new technetium cores containing technetium-nitrogen multiple bonds. Synthesis and characterization of some diazenido-hydrazido-and imidocomplexes of technetium. Polyhedron. 1990;9:1497–1502
  165. Duatti A, Marchi A, Pasqualini R. Formation of the Tc∖N multiple bond from the reaction of ammonium pertechnetate with S-methyl dithiocarbazate and its application to the preparation of technetium-99m-radiopharmaceuticals. J Chem Soc Dalton Trans. 1990;3729–3733
  166. Pasqualini R, Duatti A. Synthesis and characterisation of the new neutral myocardial imaging agent [99mTcN(noet)2] (noet=N-ethyl-Nethoxydithiocarbamato). J Chem Soc Chem Commun. 1992;1354–1355
  167. Ballinger JR, Gerson B, Gulenchyn KY. Technetium-99m dithiocarbamates as potential brain agents: Evaluation of aliphatic and amine containing analogues. Nucl Med Biol. 1989;16:721–725
  168. Treher EN, Francesconi LC, Gougoutas JZ, et al. Monocapped tris(dioxime) complexes of Technetium (III): Synthesis and structural characterisation of TcX(dioxime)3B-R (R=CH3, C4H9)(X=Cl, Br; dioxime=Dimethylglyoxime, cyclohexanedione dioxime). Inorg Chem. 1989;28:3411–3416
  169. Marmion ME, Woulfe SR, Newman WL, et al. Synthesis and characterization of novel N3O3 Schiff base complexes of 99gTc and in vivo imaging studies with analogous 99mTc complexes. Nucl Med Biol. 1996;23:567–584
  170. Banerjee S, Samuel G, Sarma HD, et al. Synthesis and radiochemical studies of 99mTc-complexes of polydentate tris-amineoximes. J Labelled Compd Radiopharm. 2000;43:1335–1344
  171. Kelly JD, Forster AM, Higley B, et al. Technetium-99m-tetrofosmine as a new radiopharmaceutical for myocardial perfsion imaging. J Nucl Med. 1993;34:222–227
  172. Katti KV, Gali H, Smith CJ, et al. Design and development of functionalized water-soluble phosphines: Catalytic and biomedical implications. Acc Chem Res. 1999;32:9–17
  173. Smith CJ, Li N, Katti KV, et al. In vitro and in vivo characterization of novel water soluble dithio-bis phosphine 99mTc complexes. Nucl Med Biol. 1997;24:685–691
  174. Karra SR, Schibli R, Gali H, et al. 99mTc-labeling and in vivo studies of a bombesin analogue with a novel water-soluble dithiadiphosphine based-bifunctional chelating agent. Bioconjugate Chem. 1999;10:254–260
  175. Liu S, Edwards DS, Harris AR. A novel ternary ligand system for Tc-99m labeling of hydrazinonicotinamide-modified biologically active molecules using imine-N-containing heterocycles as coligands. Bioconjugate Chem. 1998;9:583–595
  176. Jurisson SS, Lydon JD. Potential technetium small molecule radiopharmaceuticals. Chem Rev. 1999;99:2205–2218
  177. Nicholson T, Cook J, Davison A, et al. The synthesis and characterisation of [MCl3(N=NC5H4NH)(HN=NC5H4N)] from [MO4]− (Where M=Re, Tc) or-ganodiazenido, organodiazene-chelate complexes. Inorg Chim Acta. 1996;252:421–426
  178. Rose DJ, Maresca KP, Nicholson T. Synthesis and characterization of organohydrazino complexes of technetium, rhenium and molybdenum with the {M(η1-HxNNR)(η2-HyNNR)} core and their relationship to radiolabeled organohydrazine-derivatized chemotactic peptides with diagnostic applications. The x-ray structure of [ReCl3(N=NC5H4NH)(HN=NC5H4N). Inorg Chem. 1996;37:2701–2716
  179. Hirsch-Kuchma M, Nicholson T, Davison A, et al. The synthesis and characterisation of technetium and rhenium hydrazinopyrimidine chelate complexes. J Chem Soc Dalton Trans. 1997;18:3185–3188
  180. Edwards DS, Liu S, Barrett JA, et al. New and versatile ternary ligand system for technetium radiopharmaceuticals: Water soluble phosphines and tricene as coligand labeling a hydrazinonicotinamide-modified cyclic glycoprotein IIb/IIIa. receptor antagonist with Tc-99m. Bioconjugate Chem. 1998;9:634
  181. Rajapadhye M, Harris TD, Yu K, et al. Synthesis, evaluation and Tc-99m complexation of a hydrazinonicotinyl conjugate of GP IIb/IIIa antagonistic cyclic peptide for the detection of deep-vein thrombosis. Biorg Med Chem Lett. 1997;7:955–960
  182. Verbeke K, Hjelstucn O, Debrock E, et al. A comparative evaluation of 99Tcm-HYNIC-HSA and 99Tcm-MAG3-HSA as possible blood pool agents. Nucl Med Commun. 1995;16:942–957
  183. Visser GWM, Gerretsen M, Herscheid JDM, et al. Labeling of monoclonal antibodies with rhenium-186 using MAG3 chelate for radio-immunotherapy of cancer. A technical protocol. J Nucl Med. 1993;34:1953–1963
  184. Ram S, Buchsbaum D. A peptide-base bifunctional chelating agent for 99mTc- and 186Re-labeling of monoclonal antibodies. Cancer Res. 1994;3:769–773
  185. Lister-James J, McBride WJ, Buttram S, et al. Technetium-99m chelate-containing receptor-binding peptides. In: Nicolini M, Bandoli G, Mazzi U editor. Technetium and Rhenium in Chemistry and Nuclear Medicine. Vol 4:Padova: SG Editoriale; 1995;p. 269–274
  186. Pearson DA, Lister-James J, McBride WJ, et al. Somatostatin receptor-binding peptides labeled with technetium-99m: Chemistry and initial biological studies. J Med Chem. 1996;39:1361–1371
  187. Pearson DA, Lister-James J, McBride WJ, et al. Thrombus imaging using Technetium-99m-labeled high-potency GP IIb/IIIa receptor antagonist. Chemistry and initial biological studies. J Med Chem. 1996;39:1372–1382
  188. Liu S, Edwards DS, Harris AR, et al. 99mTc-labeling kinetics of four thiol-containing chelators and 2-hydrazinopyridine: Factor influencing their radiolabeling efficiency. Appl Radiat Isot. 1997;48:1103–1111
  189. Verbruggen AM. Bifunctional chelators for Technetium-99m. In: Mather SJ editors. Current Directions in Radiopharmaceutical Research and Development. London: Kluwer Academic Publisher; 1996;p. 31–46
  190. Seifert S, Pietzsch HJ, Scheunemann M, et al. No carrier added preparations of “3+1” mixed-ligand 99mTc complexes. Appl Radiat Isot. 1998;49:5–11
  191. Syhre R, Seifert S, Spies H, et al. Stability versus reactivity of “3+1” mixed-ligands Technetium-99m complexes in vitro and in vivo. Eur J Nucl Med. 1998;25:793–796
  192. Alberto R, Schibli R, Schubiger PA, et al. Reaction with the technetium and rhenium carbonyl complexes [NEt4][MX3(CO)3]. Synthesis and structure of [Tc(CN-rBu)3(CO)3][NO3] and [NEt4][Tc2(μ-SCH2CH2OH)3(CO)6]. Polyhedron. 1996;15:1079–1089
  193. Alberto R, Schibli R, Angst D, et al. Application of technetium and rhenium carbonyl chemistry to nuclear medicine. Transition Met Chem. 1997;22:597–601
  194. Alberto R, Schibli R, Abram U, et al. Potential of organometallic “[M(CO)3]+”(M=Re, Tc) fragment for the labeling of proteins and small molecules. Radiochim Acta. 1997;79:99–103
  195. Schibli R, Alberto R, Abram U, et al. Structural and 99Tc NMR investigations of complexes with fac-[Tc(CO)3]+ moieties and macrocyclic thioethers of various ring sizes: Synthesis and x-ray structure of the complexes fac-[Tc(9-ane-S3)(CO)3]Br, fac[Tc2(tosylate)2(18-ane-S6)(CO)6] and fac[Tc2(20-ane-S6-OH)(CO)6][tosylate]2. Inorg Chem. 1998;37:3509–3516
  196. Abram U, Abram S, Schibli R, et al. Synthesis and structures of technetium (I) and rhenium (I) tricarbonyl complexes with bis(diphenylthiophosphoryl)amide, {M(CO)3[Ph2PS)2N](CH3CN)}(M=Tc, Re). Polyhedron. 1998;17:1303–1309
  197. Alberto R, Schibli R, Egli A, et al. Metal carbonyl synthesis XXII: Low-pressure carbonylation of [MOCl4−] and [MO4−]—The technetium(I) and rhenium (I) complexes [Et4N]2[MCl3(CO)3]. J Organomet Chem. 1995;492:217–224
  198. Alberto R, Herrmann WA, Kiprof P, et al. Multiple bonds between main group elements and transition metals. Synthesis and reactivity of TcCl(CO)3[P(C6H5)3]2: Novel technetium complex of 1,4,7-triazacyclononane and hydriditris(pyrazolyl) borate. Inorg Chem. 1992;31:895–899
  199. Alberto R, Schibli R, Schubiger PA, et al. A simple single-step synthesis of [99Tc3H3(CO)12] from [99TcO4−] and its x-ray crystal structure. Application to the production of no-carrier added [188Re3H3(CO)12]. J Chem Soc Chem Commun. 1996;1291–1292
  200. Reisgys M, Wust F, Alberto R, et al. Synthesis of rhenium(I) and technetium(I) carbonyl/dithioether ligand complexes bearing 3,17β-estradiol. Bioorg Med Chem Lett. 1997;7:2243–2246
  201. Wenzel M. Tc-99m-Markierung von cymantren-analogen verbindugen mit verschiedenen substituenten-Ein neuer zugang zu Tc-99m radiodiagnostika. J Labelled Compd Radiopharm. 1992;31:641–650
  202. Wenzel M, Schulze PE: Preparation of 99mTc-cyclopentadienyl technetium tricarbonyl complexes as diagnostic agents. PCT Int WO 91, 18908
  203. Wenzel M, Saidi M. Ester der 99mTc-markierten cytectrencarbonsaure mit alkoholen cylisher amine als gehirn-affine radiodiagnostica. J Labelled Compd Radiopharm. 1993;33:77–80
  204. Top S, El Hafa H, Vessieres A, et al. Rhenium carbonyl complexes of β-estradiol derivatives with high affinity for estradiol receptors: An approach to selective organometallic radiopharmaceuticals. J Am Chem Soc. 1995;117:8372–8380
  205. Hom RK, Katzenellenbogen JA. Synthesis of a tetradentate oxorhenium (V) complex mimic of a steroidal estrogen. J Org Chem. 1997;62:6290–6297
  206. Spradau TW, Katzenellenbogen JA. Preparation of cyclopentadienyltricarbonylrhenium complexes using a double ligand transfer reaction. Organometallics. 1998;17:2009–2017
  207. Minutolo F, Katzenellenbogen JA. A convenient three-component synthesis of substituted cyclopentadienyl tricarbonyl rhenium complexes. J Am Chem Soc. 1998;120:4514–4516
  208. Minutolo F, Katzenellenbogen JA. A convenient three-component synthesis of substituted cyclopentadienyl tricarbonyl Re(I) and Tc(I) complexes and its potential for radiolabeling. In: Nicolini M, Bandoli G, Mazzi U editor. Technetium and Rhenium and Other Metals in Chemistry and Nuclear Medicin. Vol 5:Italy: SGE Editoriali; 1999;p. 109–116
  209. Spradau TW, Katzenellenbogen JA. Protein and peptide labeling with (cyclopentadienyl)tricarbonyl rhenium and technetium. Bioconjugate Chem. 1998;9:765–772
  210. Spradau TW, Edwards R, Anderson CJ, et al. Synthesis and biological evaluation of Tc-99m-cyclopentadienyltricarbonyltechnetium-labeled octreotide. Nucl Med Biol. 1999;26:1–7
  211. Fischman AJ, Babich JW, Strauss HW. A ticket to ride: Peptide radiopharmaceuticals. J Nucl Med. 1993;34:2253–2263
  212. Khaw BA, Strauss HW, Narula J. “Magic bullets”: From muskets to smart bombs. J Nucl Med. 1993;34:2264–2268
  213. Serafini AN. From monoclonal antibodies to peptides and molecular recognition units: An overview. J Nucl Med. 1993;34:533–536
  214. Blok D, Feitsma RIJ, Vermeij P, et al. Peptide radiopharmaceuticals in nuclear medicine. Eur J Nucl Med. 1999;26:1511–1519
  215. Hnatowich DJ. Recent developments in the radiolabeling of antibodies with iodine, indium and technetium. Semin Nucl Med. 1990;20:80–91
  216. Hnatowich DJ. Antibody radiolabeling, problems and promises. Nucl Med Biol. 1990;17:49–55
  217. (abstr) Schwarz A, Steinsträsser A. A novel approach to Tc-99m-labeled monoclonal antibodies. J Nucl Med. 1987;28:721
  218. Mather SJ, Ellison D. Reduction mediated technetium-99m-labeling of monoclonal antibodies. J Nucl Med. 1992;31:692–697
  219. Thakur ML, DeFulvio J, Richard MD, et al. Technetium-99m-labeled monoclonal antibodies; Evaluation of reducing agents. Nucl Med Biol. 1991;18:227–233
  220. Rhodes BA, Zamora PO, Newell KD, et al. Technetium-99m labeling of murine monoclonal antibody fragments. J Nucl Med. 1986;27:685–693
  221. Siccardi AG, Buraggi GL, Natali PG, et al. European multicentre study of antimelanoma immunoscintigraphy by means of 99mTc-labelled monoclonal antibody fragments. Eur J Nucl Med. 1990;16:317–323
  222. Dean RT, Weber R, Boutin R, et al. New facile methods of stably labeling antibodies with technetium-99m. In: Nicolini M, Bandoli G, Mazzi U editor. Technetium and Rhenium in Chemistry and Nuclear Medicine, Vol 3. Cortina International. New York: Verona and Raven Press; 1990;p. 605–608
  223. (abstr) Pak KY, Nedelman MA, Stewart R, et al. A rapid and efficient method of labeling IgG antibodies with Tc-99m and comparison to Tc-99m Fab' antibody fragments. J Nucl Med. 1989;30:793
  224. Koch P, Maecke HR. 99mTc-labeled biotin conjugate in a tumor “pretargeting” approach with monoclonal antibodies. Angew Chem Int Ed Engl. 1992;31:1507–1509
  225. Maina T, Stolz B, Albert R, et al. Synthesis, radiochemistry and biological evaluation of a new somatostatin analogue (SDZ-219-387) labeled with Technetium-99m. Eur J Nucl Med. 1994;21:437–444
  226. Hom RK, Katzenellenbogen JA. Technetium-99m-labeled receptor-specific small-molecule radiopharmaceuticals: Recent developments and encouraging results. Nucl Med Biol. 1997;24:485–498
  227. Katzenellenbogen JA, Welch MJ, Dehdashti F. The development of estrogen and progestin radiopharmaceuticals for imaging breast cancer. Anticancer Res. 1997;17:1573–1576
  228. Di Zio JP, Fiaschi R, Davison A, et al. Progestin rhenium complexes: Metal-labeled steroids with high receptor-binding affinity, potential receptor directed agents for diagnostic-imaging or therapy. Bioconjugate Chem. 1991;2:353–366
  229. O'Neil JP, Carlson KE, Anderson CJ, et al. Progestin radiopharmaceuticals labeled with technetium and rhenium: Synthesis, binding affinity, and in-vivo distribution of a new progestin N2S2-metal conjugate. Bioconjugate Chem. 1994;5:182–193
  230. Chi DY, Katzenellenbogen JA. Selective formation of heterodimeric bis-bidentate aminethiol-oxometal complexes of Rhenium(V). J Am Chem Soc. 1993;115:7045–7046
  231. Chi DY, O'Neil JP, Anderson CJ, et al. Homodimeric and heterodimeric bis(aminethiol) oxometal complexes with Rhenium(V) and Technetium(V). Control of heterodimeric complex formation and an approach to metal complexes that mimic steroid hormones. J Med Chem. 1994;37:928–937
  232. Wust F, Schuer D, Spies H, et al. Synthesis of oxorhenium(V) complexes derived from 7-alpha-functionalized testosterone derivatives. Eur J Inorg Chem. 1998;6:789–793
  233. Wust F, Spies H, Johannsen B. Synthesis of “3+1” mixed-ligand oxorhenium (V) complexes containing modified 3,17β-estradiol. Bioorg Med Chem Lett. 1996;6:2729–2734
  234. Dischino DD, Welch MJ, Kilbourn MR, et al. Relationship between lipophilicity and brain extraction of C-11-labelled radiopharmaceuticals. J Nucl Med. 1983;24:1030–1038
  235. Kung MP, Stevenson DA, Plossl K, et al. [99mTc]TRODAT-1: A novel technetium-99m complex as a dopamine transporter imaging agent. Eur J Nucl Med. 1997;24:372–380
  236. Meegalla SK, Plossl K, Kung MP, et al. Synthesis and characterisation of Tc-99m-labeled tropanes as dopamine transporter imaging agents. J Med Chem. 1997;40:9–17
  237. Meegalla SK, Plossl K, Kung MP, et al. Specificity of diasteromers of [99mTc]TRODAT-1 as dopamine transporter imaging agents. J Med Chem. 1998;41:428–436
  238. Madras BK, Jones AG, Mahmood A, et al. Technepine: A high-affinity Tc-99m probe to label the dopamine transporter in brain by SPECT imaging. Synapse. 1996;22:239–246
  239. Hoepping A, Brust P, Berger R, et al. Novel rhenium complexes derived from α-Tropanol as potential ligands for the dopamine transporter. Bioorg Med Chem. 1998;6:1663–1672
  240. Hoepping A, Reisgys M, Brust P. TROTEC-1: A new high-affinity ligand for labeling of the dopamine transporter. J Med Chem. 1998;41:4429–4432
  241. Johannsen B, Berger R, Brust P, et al. Structural modification of receptor-binding technetium-99m complexes in order to improve brain uptake. Eur J Nucl Med. 1997;24:316–319
  242. Johannsen B, Scheunemann M, Spies H, et al. Technetium(V) and Rhenium (V) complexes for 5-HT2A serotonin receptor binding: Structure affinity considerations. Nucl Med Biol. 1996;23:429–438
  243. Schenk DB, Rydel RE, May P, et al. Therapeutic approaches related to amyloid-β peptide and Alzheimer's disease. J Med Chem. 1995;38:4141–4154
  244. Han H, Cho CG, Lansbury PT. Technetium complexes for the quantitation of brain amyloid. J Am Chem Soc. 1996;118:4506–4507

PII: S0001-2998(01)80006-4

doi: 10.1053/snuc.2001.26205

Seminars in Nuclear Medicine
Volume 31, Issue 4 , Pages 260-277 , October 2001

Article Tools